Home » Author Archives: Catherine Skari (page 8)

Author Archives: Catherine Skari

Denosumab

  Update: 27 September 2019 No update available   Update: 30 July 2019 Sandoz, a Novartis division focusing on biosimilars have enrolled the first patient in an intergrated Phase I/III study for the development of denosumab for use in osteoporosis. Sources: https://www.novartis.com/news/media-releases/sandoz-announces-first-patient-enrolled-clinical-study-proposed-biosimilar-denosumab-osteoporosis   Update: 30 May 2019 No update available. ...

Read More »

Luspatercept

  ‘BELIEVE’ Study in Adults with TDT β-thalassaemia   Update: 27 September 2019 No update available   Update: 30 July 2019 The FDA has accepted the Biologics License Application (BLA) for luspatercept. The FDA has granted Priority Review to this BLA for the evaluation of the beta-thalassemia indication and set ...

Read More »

Gene Therapy

ZYNTEGLO (ex-Lentiglobin) gene therapy for patients with TDT   Update: 27 September 2019 No update available   Update: 30 July 2019 Updated results from the completed Phase 1/2 Northstar (HGB-204) study, and new data from the Phase 3 Northstar-2 (HGB-207) and Phase 3 Northstar-3 (HGB-212) clinical studies of its LentiGlobin® ...

Read More »

Gene Editing

CRISPR gene editing   Update: 27 September 2019 Enrollment in Phase 1/2 study of CTX001 in patients with TDT is ongoing. Based on the progression of the program, CRISPR Therapeutics expects to obtain preliminary safety and efficacy data in late 2019. The first patient treated with CTX001 in a Phase ...

Read More »

Hepcidin

Hepcidin trials – TRANSCEND   Update: 27 September 2019 No update available   Update: 30 July 2019 No update available.   Update: 30 May 2019 No update available.   Update: 01 February 2019 Hepcidin is a hormone that performs various functions related to iron absorption and distribution in the body.  ...

Read More »

Improving safety of blood transfusion

    INTERCEPT-treated RBCs   Update: 27 September 2019 No update available   Update: 30 July 2019 No update available.   Update: 30 May 2019 No update available.   Update: 01 February 2019 The SPARC study was a randomized, double blinded cross-over study evaluating the efficacy and safety of INTERCEPT ...

Read More »

Mr Abdul Baset Mohd Merdas

Mr. Abdel Basset Mohamed Merdas was born in the United Arab Emirates in Dubai in 1960, and holds a Bachelor Degree in Business Administration. He worked for the Dubai Government from 1989 until 2006. He is one of the founders of the Emirates Thalassemia Society (ETS), and played a major ...

Read More »